Pharma forensics is having a moment—and it’s not just for patent attorneys.
In a market where “launch dates” are often marketing, the real story is written in formulations: excipients, particle size, polymorphs, delivery systems, stability claims, and …

Designing Around the Moat: Why Secondary Formulation Patents Are the New Battleground for Generic Developers
In generic drug development, the old playbook was simple: find the primary patent, design around it, and move on. But the market has evolved—an…

Patent cliffs aren’t just a legal event—they’re a supply-chain stress test.
For years, “patent cliff” has been treated like a finance headline: a looming date when exclusivity ends and generic competition arrives. But in the real world—where procuremen…

AI is getting better at finding what patent examiners miss—because it’s learning to read between the lines.
For years, “prior art search” has been treated like a keyword game: throw the right terms into the database, filter by date, and hope the releva…

Pharma’s next IP battleground isn’t the molecule—it’s the formulation.
For years, the industry has treated “designing around” as a chemistry problem: tweak the active ingredient, change the route, move on. But in 2026, the more common—and more expensiv…

Drug patents aren’t just about the active ingredient. They’re about the how.
Most people read drug patent claims and stop at the molecule—what the drug is. But the real competitive intelligence often hides in the “boring” details: excipients, formula…

The biosimilar “patent dance” isn’t a formality—it’s the first move in a multi-year chess match.
If you’re a biologics innovator or a biosimilar applicant, you already know the headlines: the dance, the listings, the exchanges, the litigation. But th…

Generic manufacturers don’t “wait” for exclusivity—they engineer it.
In the pharmaceutical market, the first 180 days after a Paragraph IV win aren’t just a legal milestone. They’re a competitive weapon. And the companies that consistently capture th…

The Patent Dance Is Over. The Litigation Playbook Is the New Competitive Edge.
If you’re a biologics innovator—or a biosimilar applicant—you already know the choreography: the BPCIA “patent dance,” the exchanges, the timelines, the strategic disclosure…

Big Pharma loves to talk about innovation. But the real competitive edge in drug development is increasingly hiding in plain sight: the data that sits before the headlines—patent timelines, exclusivity cliffs, and the supply-chain realities that determ…